🔎 Trials Near Me

Akèy › Maladi Entestinal Anflamatwa

Etid klinik pou Maladi Entestinal Anflamatwa ap rekrite nan Etazini

71 etid pou Maladi Entestinal Anflamatwa ap rekrite patisipan nan sit atravè Etazini.

Vil ki gen plis etid

Pa eta

Etid ki fèk mete ajou

Tèks ofisyèl etid la (Anglè)

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 30, 2026 · NCT06598943

Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease

Ap rekriteEtid obsèvasyon
Laj 18 a 85 · Tout sèks · Mizajou Sep 30, 2026 · NCT07619547

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07012395

A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis

Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07845487

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT06619990

Immune Regulation in Ulcerative Colitis or Crohn s Disease

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
1 Day – 75 Years · Tout sèks · Mizajou Sep 28, 2026 · NCT00001184

Non-nutritive Sweeteners in Inflammatory Bowel Disease

Ap rekriteVolontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Sep 25, 2026 · NCT07769437

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Sep 25, 2026 · NCT05923073

Study of DISC-0974-201 in Participants With IBD and Anemia

Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07368972

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345

Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 90 · Tout sèks · Mizajou Sep 22, 2026 · NCT04685200

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Ap rekriteFaz 2
Laj 18 a 85 · Tout sèks · Mizajou Sep 22, 2026 · NCT06226883

Observational Pharmaco-Epidemiology Research & Analysis

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 0 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT03813862

Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome

Ap rekriteEtid obsèvasyon
1 Month – 115 Years · Tout sèks · Mizajou Sep 9, 2026 · NCT00001456

Familial Inflammatory Bowel Disease Early Risk

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 0 a 55 · Tout sèks · Mizajou Aug 28, 2026 · NCT07791862

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Aug 24, 2026 · NCT05509777

Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease

Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06274554

A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease

Ap rekriteEtid obsèvasyon
Laj 18 a 45 · Fanm · Mizajou Aug 11, 2026 · NCT00904878

BOOM-IBD2 Pivotal Clinical Trial

Ap rekrite
Laj 18 a 85 · Tout sèks · Mizajou Aug 6, 2026 · NCT06571669

HB-adMSCs for the Treatment of Crohn's Disease

Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Aug 6, 2026 · NCT07077746

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07237516

Impact of the Enhanced Recovery After Surgery System for Colorectal Surgery

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT02997293

Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.